Alpha-1 lung disease, commonly associated with alpha-1 antitrypsin deficiency (AATD), is an inherited condition that can increase the risk of lung damage. Alpha-1 antitrypsin is a protein that helps protect lung tissue from enzymes released during inflammation. When levels are too low or the protein does not function properly, lung tissue can become more vulnerable to damage. The condition can contribute to emphysema and chronic obstructive pulmonary disease (COPD), particularly in people who smoke or have significant exposure to lung irritants.
Alpha-1 antitrypsin deficiency is caused by inherited changes in the SERPINA1 gene.
The liver normally produces alpha-1 antitrypsin, which enters the bloodstream and helps protect the lungs. Certain genetic variants can result in insufficient functional protein reaching the lungs.
AATD can affect both the lungs and liver, although the severity varies considerably.
Lung symptoms may resemble COPD or emphysema and can include:
Symptoms can develop earlier than expected in some people, especially when smoking or other lung exposures are present.
Certain forms of AATD can also cause liver disease.
Possible signs include:
Children with severe forms can develop liver problems early in life.
Testing generally begins with measuring alpha-1 antitrypsin levels in the blood.
Additional testing may include:
Genetic testing can identify the specific SERPINA1 variant and may help with family evaluation.
Treatment focuses on protecting lung function, managing respiratory symptoms, and preventing further damage.
Possible treatments include:
Treatment is individualized according to lung function, symptoms, genetic findings, and overall health.
Augmentation therapy involves intravenous administration of purified alpha-1 antitrypsin protein.
It is designed to increase circulating levels of the protective protein and may be considered for certain individuals with severe AATD-related lung disease.
Eligibility depends on factors such as:
It does not reverse existing emphysema.
Pulmonary rehabilitation can help improve exercise capacity and manage breathlessness.
Programs may include:
Regular physical activity can help maintain strength and functional capacity.
Avoiding tobacco smoke is particularly important in AATD because smoking can accelerate lung damage.
Reducing exposure to:
may also help protect lung function.
People with AATD may need periodic liver assessment.
Monitoring can include:
Avoiding excessive alcohol consumption and discussing potentially liver-toxic medications with a healthcare professional may also be appropriate.
When lung disease becomes severe, additional respiratory support may be necessary.
Depending on individual circumstances, treatment can include:
Specialist evaluation is important when respiratory function becomes significantly impaired.
Because AATD is inherited, relatives of an affected individual may benefit from genetic counseling and testing.
Identifying the condition early can allow appropriate monitoring and help reduce exposure to factors that accelerate lung damage.
Urgent medical evaluation may be needed for:
These symptoms can indicate a serious respiratory complication.
Alpha-1 lung disease is most commonly associated with inherited alpha-1 antitrypsin deficiency, which can increase susceptibility to emphysema and COPD. Early diagnosis, avoidance of tobacco smoke, appropriate respiratory medications, pulmonary rehabilitation, and regular monitoring can help protect lung function. Eligible individuals with severe deficiency may also be considered for alpha-1 antitrypsin augmentation therapy. Ongoing lung and liver evaluation is an important part of long-term care.